PMC:7228307 / 10334-10589 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"193","span":{"begin":121,"end":125},"obj":"Gene"}],"attributes":[{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T88","span":{"begin":32,"end":36},"obj":"Body_part"}],"attributes":[{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T21","span":{"begin":69,"end":72},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0016702"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T180","span":{"begin":32,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T181","span":{"begin":121,"end":123},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T49","span":{"begin":43,"end":51},"obj":"Chemical"},{"id":"T50","span":{"begin":236,"end":244},"obj":"Chemical"}],"attributes":[{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T65","span":{"begin":32,"end":36},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T66","span":{"begin":52,"end":64},"obj":"http://purl.obolibrary.org/obo/BFO_0000034"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"193","span":{"begin":121,"end":125},"obj":"Gene"}],"attributes":[{"id":"A193","pred":"pubann:denotes","subj":"193","obj":"Gene:2213"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T57","span":{"begin":0,"end":255},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T87","span":{"begin":32,"end":36},"obj":"Body_part"}],"attributes":[{"id":"A87","pred":"fma_id","subj":"T87","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}

{"project":"LitCovid-sentences","denotations":[{"id":"T57","span":{"begin":0,"end":255},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses."}